JAMDA
Volume 10, Issue 9 , Pages 607-616 , November 2009

Erythropoiesis-Stimulating Agents in Anemia: Use and Misuse

  • T.S. Dharmarajan, MD, FACP, AGSF

      Affiliations

    • New York Medical College, Valhalla, NY
    • Department of Medicine, Division of Geriatrics, and Geriatric Medicine Fellowship Program, Montefiore Medical Center (North Division), Bronx, NY
    • Corresponding Author InformationAddress correspondence to T.S. Dharmarajan, MD.
    • ,
  • David Widjaja, MD

      Affiliations

    • Department of Medicine, Bronx Lebanon Hospital Center, Bronx, NY

References 

  1. Dharmarajan TS, Widjaja D. Erythropoiesis-stimulating agents in anemia. Geriatrics. 2008;63:13–29
  2. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471–530
  3. Kdoqi , National Kidney F. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006;47:S16–S85
  4. Denker BM. Erythropoietin: From bench to bedside. Nephrology Rounds. 2004;2:1–6
  5. Nurko S. Anemia in chronic kidney disease: Causes, diagnosis, treatment. Cleve Clin J Med. 2006;73:289–297
  6. Agarwal AK. Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly. J Am Med Dir Assoc. 2006;7:S7–S12quiz S17–21
  7. Fisher JW. Erythropoietin: Physiology and pharmacology update. Exp Biol Med (Maywood). 2003;228:1–14
  8. Reissmann KR. Studies on the mechanism of erythropoietic stimulation in parabiotic rats during hypoxia. Blood. 1950;5:372–380
  9. Kuratowska Z, Lewartowski B, Michalak E. Studies on the production of erythropoietin by isolated perfused organs. Blood. 1961;18:527–534
  10. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A. 1985;82:7580–7584
  11. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985;313:806–810
  12. Eschbach JW, Kelly MR, Haley NR, et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 1989;321:158–163
  13. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001;84:3–10
  14. Lacombe C, Mayeux P. Biology of erythropoietin. Haematologica. 1998;83:724–732
  15. Koury ST, Bondurant MC, Koury MJ, et al. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood. 1991;77:2497–2503
  16. Fandrey J, Bunn HF. In vivo and in vitro regulation of erythropoietin mRNA: Measurement by competitive polymerase chain reaction. Blood. 1993;81:617–623
  17. Tan CC, Eckardt KU, Ratcliffe PJ. Organ distribution of erythropoietin messenger RNA in normal and uremic rats. Kidney Int. 1991;40:69–76
  18. Masuda S, Okano M, Yamagishi K, et al. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem. 1994;269:19488–19493
  19. Eckardt KU, Kurtz A. Regulation of erythropoietin production. Eur J Clin Invest. 2005;35:13–19
  20. Finch CA. Erythropoiesis, erythropoietin, and iron. Blood. 1982;60:1241–1246
  21. Information on Erythropoiesis Stimulating Agents (ESA) (marketed as Procrit, Epogen, and Aranesp). Information for Healthcare Professionals. Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE200711HCP.htm. Accessed December 28, 2008.
  22. Donnelly S. Why is erythropoietin made in the kidney? The kidney functions as a critmeter. Am J Kidney Dis. 2001;38:415–425
  23. Mayeux P, Billat C, Jacquot R. The erythropoietin receptor of rat erythroid progenitor lens. Characterization and affinity cross-linkage. J Biol Chem. 1987;262:13985–13990
  24. Elliott S, Pham E, Macdougall IC. Erythropoietins: A common mechanism of action. Exp Hematol. 2008;36:1573–1584
  25. Kieran MW, Perkins AC, Orkin SH, et al. Thrombopoietin rescues in vitro erythroid colony formation from mouse embryos lacking the erythropoietin receptor. Proc Natl Acad Sci U S A. 1996;93:9126–9131
  26. Socolovsky M, Dusanter-Fourt I, Lodish HF. The prolactin receptor and severely truncated erythropoietin receptors support differentiation of erythroid progenitors. J Biol Chem. 1997;272:14009–14012
  27. Silva M, Grillot D, Benito A, et al. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood. 1996;88:1576–1582
  28. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA. 2005;293:90–95
  29. Chong ZZ, Kang JQ, Maiese K. Angiogenesis and plasticity: role of erythropoietin in vascular systems. J Hematother Stem Cell Res. 2002;11:863–871
  30. Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Prevalence of anemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia. Blood. 2004;104:2263–2268
  31. Steensma DP, Tefferi A. Anemia in the elderly: How should we define it, when does it matter, and what can be done?. Mayo Clin Proc. 2007;82:958–966
  32. Dharmarajan TS, Norkus EP. Mild anemia and the risk of falls in older adults from nursing homes and the community. J Am Med Dir Assoc. 2004;5:395–400
  33. Dharmarajan TS, Avula S, Norkus EP. Anemia increases risk for falls in hospitalized older adults: An evaluation of falls in 362 hospitalized, ambulatory, long-term care, and community patients. J Am Med Dir Assoc. 2007;8:e9–e15
  34. Beard CM, Kokmen E, O'Brien PC, et al. Risk of Alzheimer's disease among elderly patients with anemia: Population-based investigations in Olmsted County, Minnesota. Ann Epidemiol. 1997;7:219–224
  35. Kikuchi M, Inagaki T, Shinagawa N. Five-year survival of older people with anemia: Variation with hemoglobin concentration. J Am Geriatr Soc. 2001;49:1226–1228
  36. Culleton BF, Manns BJ, Zhang J, et al. Impact of anemia on hospitalization and mortality in older adults. Blood. 2006;107:3841–3846
  37. Dharmarajan TS, Pankratov A, Morris E, et al. Anemia: Its impact on hospitalizations and length of hospital stay in nursing home and community older adults. J Am Med Dir Assoc. 2008;9:354–359
  38. Agnihotri P, Telfer M, Butt Z, et al. Chronic anemia and fatigue in elderly patients: Results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa. J Am Geriatr Soc. 2007;55:1557–1565
  39. Dharmarajan TS. Anemia and response to epoetin alfa: The cause of anemia matters!. J Am Geriatr Soc. 2008;56(8):1574–1575
  40. Kario K, Matsuo T, Nakao K. Serum erythropoietin levels in the elderly. Gerontology. 1991;37:345–348
  41. Kario K, Matsuo T, Kodama K, et al. Reduced erythropoietin secretion in senile anemia. Am J Hematol. 1992;41:252–257
  42. Joosten E, Van Hove L, Lesaffre E, et al. Serum erythropoietin levels in elderly inpatients with anemia of chronic disorders and iron deficiency anemia. J Am Geriatr Soc. 1993;41:1301–1304
  43. Cody J, Daly C, Campbell M, et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev. 2001;(4):CD003266
  44. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  45. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  46. Coyne DW. The TREAT study answers a question, not the question. Am J Kidney Dis. 2008;52:626–627author reply 627–628
  47. Pfeffer MA. An ongoing study of anemia correction in chronic kidney disease. N Engl J Med. 2007;356:959–961
  48. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255–1260
  49. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol. 2005;23:5960–5972
  50. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25:1027–1032
  51. Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med. 2007;356:2445–2448
  52. Balducci L. Cancer-related anemia: Special considerations in the elderly. Oncology (Williston Park). 2007;21:81–8690; discussion 90, 100,104
  53. Information on Erythropoiesis Stimulating Agents (ESA) (marketed as Procrit, Epogen and Aranesp). Prescribing information. Available at: http://www.fda.gov/cder/drug/infopage/RHE/default.htm. Accessed January 1, 2008, 2008.
  54. Feagan BG, Wong CJ, Kirkley A, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med. 2000;133:845–854
  55. Baudoux E. Autologous blood donation plus epoetin alfa in nonanemic orthopedic surgery patients. Semin Hematol. 1996;33:31–32discussion 33
  56. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003;90:446–455
  57. Marti-Carvajal AJ, Sola I. Treatment for anemia in people with AIDS. Cochrane Database Syst Rev. 2007;(1):CD004776
  58. Camacho J, Poveda F, Zamorano AF, et al. Serum erythropoietin levels in anaemic patients with advanced human immunodeficiency virus infection. Br J Haematol. 1992;82:608–614
  59. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004;351:1403–1408
  60. Wish JB, Coyne DW. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: Overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. Mayo Clin Proc. 2007;82:1371–1380
  61. Dharmarajan TS, Sohagia A, Norkus EP. The diagnosis and management of anemia in chronic kidney disease in long term care. Long-term Care Interface. 2007;8:47–51
  62. Balducci L. Epidemiology of anemia in the elderly: Information on diagnostic evaluation. J Am Geriatr Soc. 2003;51:S2–S9
  63. Wish JB. Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1:S4–S8
  64. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood. 2000;96:823–833
  65. Macdougall IC, Cooper AC. Erythropoietin resistance: The role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2002;17:39–43
  66. Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr. 2006;26:323–342
  67. Fishbane S. Upper limit of serum ferritin: Misinterpretation of the 2006 KDOQI anemia guidelines. Semin Dial. 2008;21:217–220
  68. Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005;118:1142–1147
  69. Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology Am Soc Hematol Educ Program. 2003;40–61
  70. Dharmarajan TS, Bullecer MLF, Bhagwati N. Hematologic disorder in older adults. In:  Dharmarajan TS,  Norman RA editor. Clinical Geriatrics. New York, NY: The Parthenon Publishing Group; 2003;p. 490
  71. Mikhail A, Covic A, Goldsmith D. Stimulating erythropoiesis: Future perspectives. Kidney Blood Press Res. 2008;31:234–246
  72. Schellekens H. The first biosimilar epoetin: But how similar is it?. Clin J Am Soc Nephrol. 2008;3:174–178
  73. Macdougall IC. Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: A randomized controlled trial. Trials. 2007;8:35
  74. Curran MP, McCormack PL. Methoxy polyethylene glycol-epoetin beta: A review of its use in the management of anaemia associated with chronic kidney disease. Drugs. 2008;68:1139–1156
  75. Sulowicz W, Locatelli F, Ryckelynck JP, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007;2:637–646
  76. Macdougall IC, Walker R, Provenzano R, et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: Results of a randomized clinical trial. Clin J Am Soc Nephrol. 2008;3:337–347
  77. Singh A, Patel T, Hertel J, et al. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis. 2008;52:907–915
  78. Thomas DR. Anemia: It's all about quality of life. J Am Med Dir Assoc. 2007;8:80–82

PII: S1525-8610(09)00176-5

doi: 10.1016/j.jamda.2009.05.003

JAMDA
Volume 10, Issue 9 , Pages 607-616 , November 2009

Article Tools

* Image Usage & Resolution